ORAMED PHARMACEUTICALS INC. | 2013 | FY | 3


         
Period from April
 
            12, 2002  
         
(inception)
 
   
Year ended
   
through
 
   
August 31,
   
August 31,
 
   
2013
   
2012
      2013  
                     
Clinical trials
  $ 1,341,471     $ 1,298,310     $ 6,504,824  
Payroll and consulting fees
    447,195       385,646       2,368,728  
Costs for registration of patents
    106,687       110,811       558,297  
Compensation costs in respect of options granted to employees, directors and consultants
    346,961       98,688       3,268,842  
Other
    338,635       160,350       886,242  
Less - grants from the OCS and Bio Jerusalem Fund
    (309,155 )     (372,959 )     (1,782,445 )
    $ 2,271,794     $ 1,680,845     $ 11,804,488  

us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersTextBlock